Ankylosing Spondylitis

Sclerostin in ankylosing spondylitis: A meta-analysis.

Jiang LW, Yuan ML, Jiang LN, Xia AX, Chen JQ, Li YP · Clinica chimica acta; international journal of clinical chemistry · 2025

This study aims to assess circulating sclerostin levels in patients with ankylosing spondylitis (AS). The databases of PubMed, Embase, Medline, Web of Science, The Cochrane Library, China National Knowledge Infrastructure Database (CNKI), China Biomedical Literature Database (CBM), Wanfang Med Online Database (Wanfang), China Science and Technology Journal Database (VIP) were used to collect all relevant published articles (up to 26 August 2024). The pooled standardized mean difference (SMD) with 95% confidence interval (CI) was calculated by the random-effect model. A total of 22 studies were included, including 1354 AS patients and 871 normal controls. There was no significant difference in the circulating sclerostin levels between AS patients and normal controls (SMD = -0.03, 95%CI = -0.51 to 0.46, P = 0.92). Subgroup analysis showed that the South America group, the Africa group, cohort study group, bath ankylosing spondylitis disease activity index (BASDAI) s

Bone density and fracture risk factors in ankylosing spondylitis: a meta-analysis.

Yan F, Wu L, Lang J, Huang Z · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024

We included 39 studies in our meta-analysis, finding that patients with ankylosing spondylitis (AS) exhibit decreased bone mineral density (BMD) and an elevated risk of fractures. Additionally, we analyzed the risk factors associated with fractures in these patients. AS is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, with reduced BMD, osteoporosis, and fractures being common complications. This study aims to systematically consolidate and conduct a meta-analysis of existing research to comprehensively understand decreased bone mineral density, osteoporosis, and fracture risks at various anatomical sites in AS patients. The objective is to provide reliable information for the management of AS patients and to inform clinical decision making. We conducted a thorough search in various databases including Embase, PubMed, Cochrane Library, and Web of Science. These studies focused on the risk of and risk factors for decre

Effectiveness of exercise intervention in relieving symptoms of ankylosing spondylitis: A network meta-analysis.

Luo Y, Chen Y, Yan X, Zhang L, Shang Y, Seo JC · PloS one · 2024

Ankylosing spondylitis(AS) is a chronic inflammatory rheumatic disease that leads to a reduced quality of life. Exercise appears to be one of the promising modes of intervention. The aim of this study was to review the available evidence and compare the effectiveness of different exercises in relieving symptoms of AS. We searched the Pubmed, WOS, EMbase, CNKI, Cochrane Library, and Scopus databases. The search has spanned from the creation of the database until September 15, 2023. We extracted the first author, year of article publication, sample information, intervention, duration of intervention, and outcome indicators from the literature that met the inclusion criteria. The Cochrane Risk Assessment Tool was used to assess the risk of bias for included studies. I² was used to judge the consistency of the included studies. Egger's test and Begg's test were used to judge whether there was significant publication bias. Forest plots were used to compare intervention effects and SUC

Yoga in autoimmune disorders: a systematic review of randomized controlled trials.

Baishya A, Sharma S, Hazarika D, Saini S, Sharma H, Metri K · Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025 · n=960

Yoga, a mind-body therapy, is widely utilized for managing health outcomes in autoimmune disorders (ADs). Despite its extensive use, no systematic review has been conducted to assess the impact of yoga on ADs. The objective was to evaluate the evidence of yoga on health outcomes in ADs based on randomized controlled trials (RCTs). A comprehensive search was conducted across Scopus, Web of Science, PubMed, Medline, and PsycINFO from January 2000 to June 2024, as well as relevant reference lists. RCTs evaluating the efficacy of yoga-based interventions with at least 8 weeks duration in the 5 most commonly studied ADs-multiple sclerosis (MS), rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD), and autoimmune periodontitis-were included. The methodological quality was assessed using the PEDro scale. Vote counting based on the direction of effect was used to determine effectiveness. Twenty-six RCTs involving 1,960 patients with intervention durations

Acupuncture therapy in autoimmune diseases: A narrative review.

Gamus D, Shoenfeld Y · Autoimmunity reviews · 2025

We provide a narrative review of experimental and clinical evidence for the effect of acupuncture in autoimmune diseases, based on randomized controlled studies, systematic review and meta-analyses, published between the years 2000-2023. Acupuncture in experimental models of rheumatoid arthritis (RA), multiple sclerosis, psoriasis, ulcerative colitis (UC) downregulated inflammatory cytokine expression, increased IL-10 expression, improved Treg cell differentiation, and also modulated macrophage polarization in RA and UC models. The anti-inflammatory effect of acupuncture in autoimmune disorders has been demonstrated to involve vagal-adrenal and cholinergic anti-inflammatory pathways. The analgesic effect of acupuncture involves both peripheral and central anti-nociceptive mechanisms. Randomized controlled studies support the use of acupuncture in rheumatoid arthritis, fibromyalgia, Crohn's disease and in Sjogren's syndrome. Some evidence indicates that acupuncture may be beneficial as

Homeopathy for Rheumatological Diseases: A Systematic Review.

Freire de Carvalho J, Lerner A, Benzvi C · European journal of rheumatology · 2024 · n=811

Homeopathy has mainly been used to treat several diseases. On the other hand, it has been used in a few rheumatic disorders. The aim of this article is to review the use of homeopathy in rheumatic diseases (RDs). PubMed and Embase databases were examined for literature on homeopathy and RDs between 1966 and April 2023. There are 15 articles found with 811 patients. The diseases treated were osteoarthritis (n=3), followed by rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), hyperuricemia (n=1), and tendinopathy (n=1). Age varied from 31 to 87 years old, and male gender ranged from 56.7% to 100%. Homeopathy changed from a fixed medicine to an individualized homeopathy. Most studies (9/15) demonstrated improvements after homeopathy. Side effects were not seen or minimal and were comparable to placebo groups. In conclusion, this review shows homeopathy is a promising and safe therapy for RD treatment. However, the data needs to be reproduced in future more extensive studies, includ

Ankylosing spondylitis and non-radiographic axial spondyloarthritis: assessing and managing

NICE

This NICE quality standard covers assessing and managing ankylosing spondylitis and non-radiographic axial spondyloarthritis. It aims to improve the quality of care for people with these conditions.

Ankylosing spondylitis and non-radiographic axial spondyloarthritis: diagnosis and management

NICE

This guideline covers diagnosing and managing ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults. It aims to improve early diagnosis and optimize treatment to reduce pain and disability.

Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial.

Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L · Arthritis & rheumatology (Hoboken, N.J.) · 2025 · n=187

This randomized, double-blind, adaptive phase 2/3 trial aimed to evaluate the efficacy and safety of ivarmacitinib, a novel selective JAK1 inhibitor, in patients with active ankylosing spondylitis (AS). In phase 2, patients were randomized (1:1:1:1) to receive ivarmacitinib at a dose of 2, 4, or 8 mg or placebo once daily for 12 weeks. Based on interim analysis, ivarmacitinib 4 mg was selected as the recommended dose. In phase 3, patients were randomized (1:1) to receive ivarmacitinib 4 mg or placebo for 12 weeks; from week 12 onward, all patients received ivarmacitinib 4 mg once daily through week 24. The primary end point was the proportion of patients achieving a ≥20% improvement in the Assessment of SpondyloArthritis international Society (ASAS20) response criteria at week 12. During the entire study, 504 patients were randomized (ivarmacitinib 4 mg, n = 187; placebo, n = 186). At week 12, the ASAS20 response rate was significantly higher in the ivarmacitinib 4 mg group co

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.

Deodhar A, Akar S, Curtis JR, El-Zorkany B, Magrey M, Wang C · Advances in rheumatology (London, England) · 2024

Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib 5 mg twice daily [BID] [n = 185]; placebo [n = 187]); 48-week only-tofacitinib 5 mg BID (n = 316); 48-week all-tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n = 420). Baseline 10-year atherosclerotic cardiovascular disease (ASCVD) risk was determined in patients without history of ASCVD (48-week cohorts). Adverse events (AEs)/AEs of special interest were evaluated/compared with findings from other tofacitinib programs (16 Phase 2/Phase 3 rheumatoid arthritis [RA]; 2 Phase 3 psoriatic arthritis [PsA] RCTs) and a real-world cohort of AS patients initiating biologi

Characterization of immune features and discovery of potential biomarkers for ankylosing spondylitis using deep plasma proteomics.

Xu X, Liu W, Pang B, Wang Y, Zhen H, Jiang Q · Journal of advanced research · 2026 · n=104

Ankylosing spondylitis (AS) is a systemic inflammatory disorder that predominantly involves the axial skeleton, often leading to irreversible structural damage and disability. Although several therapeutic measurements are available, limitations in efficacy and long-term outcomes remain significant. Therefore, identifying novel biomarkers and therapeutic targets is of critical importance for optimizing clinical management and prognostic evaluation in AS patients. This study aims to elucidate the immune features and discover potential biomarkers for AS by the integration of deep plasma proteomics and deep learning strategies. The deep quantitative proteomics was applied to analyze the plasma samples from 104 participants of AS patients with active and stable stages, along with healthy controls. The immune and functional features of AS patients in different stages were assessed. By integrating random forest (RF) with orthogonal partial least squares discriminant analysis (OPLS-DA), a ma

Ankylosing spondylitis and kinesiophobia.

Ertem U · PeerJ · 2025

Ankylosing spondylitis (AS) is a chronic rheumatic disease that predominantly affects the axial skeleton, causing pain and functional impairment. Kinesiophobia, or fear of movement, is common in patients with chronic pain conditions and can significantly hinder treatment outcomes. This study aims to assess the level of kinesiophobia in AS patients and explore its relationship with demographic characteristics, disease duration, pain intensity, disease activity, and functional impairment. This single-center study included 35 AS patients from July 2021 to July 2023. Patient demographics, disease duration, disease activity (BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)), functionality (BASFI (Bath Ankylosing Spondylitis Functional Index)), pain intensity (VAS (Visual Analog Scale)), and kinesiophobia (TSK (Tampa Scale of Kinesiophobia)) were recorded and analyzed. Patients were categorized into low and high kinesiophobia groups based on TSK scores. Of the 35 AS patients, 15

Tele-Rehabilitation in Ankylosing Spondylitis: Current Evidence and Future Directions in Remote Physiotherapy.

Gakhar H, Khurana K, Kataria DC · Musculoskeletal care · 2025

Ankylosing spondylitis (AS) is a chronic, immune-mediated inflammatory condition that primarily affects the axial skeleton, leading to pain, stiffness, and functional limitations. While physiotherapy plays a critical role in the management of AS, access to in-person services remains limited, particularly in rural or underserved areas. This narrative review aims to synthesise current evidence on the effectiveness and feasibility of tele-rehabilitation for individuals with ankylosing spondylitis and to identify future directions for optimising remote physiotherapy in clinical practice. A comprehensive search was conducted across four major databases: PubMed, Scopus, Web of Science, and Google Scholar. Studies published between 2008 and 2025 were selected using keywords such as ankylosing spondylitis, tele-rehabilitation, remote physiotherapy, and digital health. Eligible studies included randomized controlled trials, systematic reviews and observational studies that evaluated remote ph

Multiomics Identifies Potential Biomarkers in Ankylosing Spondylitis Bone Formation.

Yang L, Bo C, Chen M, Chen B, Zeng R, Zhou Y · Human mutation · 2025

Objective: Ankylosing spondylitis (AS) is a long-term inflammatory condition characterized by intricate pathogenesis and significant genetic predisposition. Current treatment methods cannot completely halt the progression of the disease. The purpose of this research is to discover possible therapeutic targets for AS by integrating Mendelian Randomization (MR), transcriptomics analysis, and machine learning, providing new options for the clinical treatment of AS. Methods: In this study, we initially pinpointed differentially expressed genes (DEGs) linked to AS from the GEO database and acquired cis-eQTL data for these genes from the eQTLGen Consortium. Using MR and summary data-based Mendelian randomization (SMR) analyses, we screened for DEGs with causal relationships to AS. Subsequently, we analyzed the correlation between these causal genes and immune cell expression, constructed a risk prediction model, and identified key feature genes for AS. Next, we conducted phenome-wide associa

Ankylosing spondylitis

NHS

The NHS pages offer a detailed overview of ankylosing spondylitis, covering symptoms, diagnosis, treatments, and living with the condition. It's a key resource for UK residents seeking health information.

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

n=80 · NCT04746196 · COMPLETED · COMPLETED

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Efficacy and Safety Study of Anbainuo in Chinese Patients With Rheumatoid Arthritis/ Ankylosing Spondylitis in the Real World: a Prospective, Open-label, Multi-center Observational Study

n=1000 · NCT03636984 · UNKNOWN · UNKNOWN

TNF- α receptor inhibitors have been used widely in practice and are well developed in China. Anbainuo is a bio-similar recombinant TNF-α receptor: IgG Fc fusion protein, approved in 2015. Up to now, Anbainuo is well applied in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Although the phase II and III clinical trials both indicated that Anbainuo can effectively control the disease activity with good tolerance and safety in RA and AS patients, there is no sufficient clinical evidence in the real world. Thus, the objective of this study is to evaluate, under the actual conditions of use, dosing patterns of Anbainuo. Investigators plan to recruit 1000 adult patients with RA or AS and to follow them for 48 weeks. It is hypothesized that this study would reflect real clinical conditions (efficacy and safety assessment) of using Anbainuo in RA and AS patients.

Study of the Genetic Susceptibility to Ankylosing Spondylitis by Functional Genomics Approach

n=97 · NCT02525042 · COMPLETED · COMPLETED

The main objective is to identify in the candidate regions of differentially expressed genes by comparing the transcriptome of dendritic cells derived from circulating monocytes between cases and controls. Cases and family controls will be matched on the presence of HLA-B27 and depending on haplotype association studies to correlate the differences of gene expression and genetic variations with susceptibility to AS.

TRIP Database: Ankylosing Spondylitis

TRIP Database · Strength: null

A clinical search engine designed to allow users to quickly and easily find high-quality research evidence to support their practice, including on ankylosing spondylitis.

TRIP Database - Ankylosing Spondylitis

TRIP Database

A clinical search engine providing fast access to high-quality research evidence, including guidelines, systematic reviews, and primary research, on ankylosing spondylitis.

Cochrane reviews on Ankylosing Spondylitis

Cochrane

The Cochrane Library provides a collection of systematic reviews and meta-analyses pertaining to various interventions and aspects of Ankylosing Spondylitis.